TY - JOUR
T1 - The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
AU - Qvigstad, Christian
AU - Tait, Robert Campbell
AU - Rauchensteiner, Stephan
AU - Berntorp, Erik
AU - De Moerloose, Philippe
AU - Schutgens, Roger E.
AU - Holme, Pål Andre
N1 - Funding Information:
Funding/support: The ADVANCE Working Group is supported by grant funding from Bayer Healthcare. The sponsor played no role in data collection, but was present in meetings and discussions related to the study. SR is an employee of Bayer Consumer Care AG.
Publisher Copyright:
© 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Chronic liver disease (CLD) is frequently seen in the hemophilia population. The ADVANCE Working Group conducted a cross-sectional study in which people with hemophilia (PWH) aged ≥40 years were included. This study aimed to assess the associations between CLD and its risk factors using data from the H3 study, and to suggest implications for optimal care. Data from 13 European countries were collected at a single time-point (2011-2013). Univariate and multivariate logistic regression (MLR) analyses were performed. A total of 532 PWH were included with either hemophilia A (n = 467) or hemophilia B (n = 65). A total of 127 (24%) were diagnosed with CLD. Hepatitis C virus (HCV), human immunodeficiency virus (HIV), total cholesterol, and severe hemophilia were significant risk factors in univariate logistic regressions. In MLR, HCV Ab+/PCR+ (OR = 17.6, P < .001), diabetes (OR = 3.0, P = .02), and HIV (OR = 1.9, P = .049) were positively associated with CLD. Total cholesterol (OR = 0.6, P = .002) was negatively associated with CLD. We found no evidence of interaction effects among the explanatory variables. No significant associations with age and type of or severity of hemophilia were observed in MLR. The main risk factors for CLD in this European cohort also apply to the general population, but the prevalence of HCV and HIV is considerably larger in this cohort. With new and improved treatment options, intensified eradication therapy for HCV seems justified to prevent CLD. Similarly, intensified monitoring and treatment of diabetes seem warranted.
AB - Chronic liver disease (CLD) is frequently seen in the hemophilia population. The ADVANCE Working Group conducted a cross-sectional study in which people with hemophilia (PWH) aged ≥40 years were included. This study aimed to assess the associations between CLD and its risk factors using data from the H3 study, and to suggest implications for optimal care. Data from 13 European countries were collected at a single time-point (2011-2013). Univariate and multivariate logistic regression (MLR) analyses were performed. A total of 532 PWH were included with either hemophilia A (n = 467) or hemophilia B (n = 65). A total of 127 (24%) were diagnosed with CLD. Hepatitis C virus (HCV), human immunodeficiency virus (HIV), total cholesterol, and severe hemophilia were significant risk factors in univariate logistic regressions. In MLR, HCV Ab+/PCR+ (OR = 17.6, P < .001), diabetes (OR = 3.0, P = .02), and HIV (OR = 1.9, P = .049) were positively associated with CLD. Total cholesterol (OR = 0.6, P = .002) was negatively associated with CLD. We found no evidence of interaction effects among the explanatory variables. No significant associations with age and type of or severity of hemophilia were observed in MLR. The main risk factors for CLD in this European cohort also apply to the general population, but the prevalence of HCV and HIV is considerably larger in this cohort. With new and improved treatment options, intensified eradication therapy for HCV seems justified to prevent CLD. Similarly, intensified monitoring and treatment of diabetes seem warranted.
KW - Chronic liver disease
KW - CLD
KW - Diabetes
KW - HCV
KW - Hemophilia
KW - HIV
KW - PWH
KW - Prevalence
KW - Cross-Sectional Studies
KW - Humans
KW - Middle Aged
KW - Risk Factors
KW - End Stage Liver Disease/diagnosis
KW - Hepatitis C, Chronic/epidemiology
KW - Male
KW - Aging/physiology
KW - Hemophilia B/complications
KW - Europe/epidemiology
KW - Hemophilia A/complications
KW - Adult
KW - Female
KW - Disease Management
KW - HIV Infections/epidemiology
KW - Needs Assessment
UR - http://www.scopus.com/inward/record.url?scp=85054384857&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000012551
DO - 10.1097/MD.0000000000012551
M3 - Article
C2 - 30278553
AN - SCOPUS:85054384857
SN - 0025-7974
VL - 97
SP - e12551
JO - Medicine (United States)
JF - Medicine (United States)
IS - 39
M1 - e12551
ER -